All News

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

Online systems, including telehealth, are imperative to maintaining optimal care for patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic, said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers, in an interview with The American Journal of Managed Care® (AJMC®).

This week, the top managed care news included HHS' plans to allocate the remaining $70 billion in COVID-19 funding to providers; an analysis finding aggressive social distancing measures economically justified; highlights from this week's virtual Community Oncology Conference.

The FDA granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) as the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) that has spread to other parts of the body.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo